PT -期刊文章盟埃里卡麦肯齐盟Andrew Lim - AU -爱德华梁AU -安德鲁·科尔盟罗德里戈塞加西亚AU -爱丽丝Lam盟罗纳德·Thibert AU - Bui盟以斯帖Damber Nirola AU - Sonam Deki盟Lhab Tshering AU -谎言李盟莎拉克拉克AU -约瑟夫·科恩AU -乔Mantia AU -凯特Brizzi AU -莎拉Wahlster盟斜面俗非盟-麦克尔- Aagaard盟Arkadiusz Stopczynski AU -拉斯汉森盟-悉尼现金AU -法拉Mateen TI -智能手机的验证大脑扫描仪检测癫痫痫性放电的门诊病人在不丹(S52.003) DP - 2016年4月05 TA -神经病学PG - S52.003 VI - 86 IP - 16补充4099 - //www.ez-admanager.com/content/86/16_Supplement/S52.003.short 4100 - //www.ez-admanager.com/content/86/16_Supplement/S52.003.full所以Neurology2016 4月05;首页86 AB -目的:评估智能手机的大脑Scanner-2 (SBS2)的能力检测异常和癫痫样的皮层放电相比,标准的脑电图(EEG)在癫痫患者(PWE)在不丹。背景:SBS2是一个软件应用程序,利用14-lead耳机无线连接到一个Android设备。便携、容易操作,低成本(每设备& lt; 500美元),SBS2可能帮助癫痫的诊断在资源有限的环境中。方法:PWE或疑似癫痫在不丹接受SBS2和标准脑电图(每个时间≥20分钟)。使用的SBS2 circumference-matched EasyCaps环电极定位在F3, C3, P3, O1, F4, C4, P4, O2, Fz, Cz, Pz Fpz A1, A2。标准的脑电图(Xltek Natus) 10 - 20系统使用电极位置和外围线索。神经学家,盲法临床数据,记录分类为正常或异常,异常癫痫样的或背景。每个SBS2录音读一次。每个标准脑电图被≥2神经学家独立评估。 A third neurologist or a group of neurologists resolved discrepancies. Results: 215 participants (53[percnt] female, mean age 25 years) completed both SBS2 and standard EEG with no safety or tolerability concerns. Epileptiform discharges were present on 25[percnt] and 15[percnt] of standard and SBS2 EEGs. For the detection of all abnormalities, the SBS2 had a sensitivity of 0.51, specificity of 0.84, and positive and negative predictive values of 0.65 and 0.74 versus standard EEG. For the detection of epileptiform discharges, the SBS2 had a sensitivity of 0.36, specificity of 0.94, and positive and negative predictive values of 0.68 and 0.84 versus standard EEG. Conclusions: The SBS2 EEG is specific but not sensitive for the detection of epileptiform discharges, and may have clinical relevance to help confirm a suspected epilepsy diagnosis in resource-limited settings. Sensitivity may be improved with hardware modifications including the addition of electrodes along the temporal chain.Disclosure: Dr. McKenzie has nothing to disclose. Dr. Lim has received personal compensation for activities with UCB Pharma as a consultant. Dr. Leung has nothing to disclose. Dr. Cole has received personal compensation for activities with Clarus Ventures and Sage Therapeutics as a consultant. Dr. Zepeda Garcia has nothing to disclose. Dr. Lam has nothing to disclose. Dr. Thibert has nothing to disclose. Dr. Bui has received personal compensation for activities with UCB as a speaker. Dr. Nirola has nothing to disclose. Dr. Deki has nothing to disclose. Dr. Tshering has nothing to disclose. Dr. L. Lee has received personal compensation for activities with Novartis Canada, EMD Serono Canada, and Biogen Idec as a consultant. Dr. Clark has nothing to disclose. Dr. Cohen has nothing to disclose. Dr. Mantia has nothing to disclose. Dr. Brizzi has nothing to disclose. Dr. Wahlster has nothing to disclose. Dr. Sorets has nothing to disclose. Dr. Aagaard has nothing to disclose. Dr. Stopczynski has nothing to disclose. Dr. Hansen has nothing to disclose. Dr. Cash has nothing to disclose. Dr. Mateen has nothing to disclose.Thursday, April 21 2016, 3:30 pm-5:30 pm